Russell Investments Group Ltd. Sells 222,114 Shares of CareDx, Inc (NASDAQ:CDNA)

Russell Investments Group Ltd. trimmed its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 41.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 313,259 shares of the company's stock after selling 222,114 shares during the period. Russell Investments Group Ltd. owned 0.58% of CareDx worth $6,707,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CDNA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of CareDx during the third quarter worth approximately $1,671,000. Geode Capital Management LLC boosted its stake in shares of CareDx by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company's stock valued at $38,343,000 after buying an additional 32,141 shares during the period. Swiss National Bank increased its stake in shares of CareDx by 1.9% in the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock worth $2,111,000 after acquiring an additional 1,800 shares during the last quarter. Barclays PLC raised its holdings in shares of CareDx by 123.8% during the third quarter. Barclays PLC now owns 98,505 shares of the company's stock worth $3,075,000 after acquiring an additional 54,482 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in CareDx by 59.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock valued at $7,008,000 after purchasing an additional 122,356 shares during the last quarter.

CareDx Price Performance

NASDAQ:CDNA traded down $0.60 during midday trading on Friday, reaching $17.62. The stock had a trading volume of 537,147 shares, compared to its average volume of 852,165. The stock has a market capitalization of $976.61 million, a P/E ratio of -6.53 and a beta of 2.18. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The firm's fifty day simple moving average is $19.73 and its 200-day simple moving average is $22.38.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. On average, equities research analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CDNA has been the topic of several research reports. The Goldman Sachs Group dropped their target price on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday. Stephens reaffirmed an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. HC Wainwright cut their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Finally, Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and decreased their price objective for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $30.33.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.